Rethinking Cholesterol: New AHA/ACC Guidelines Reshape How to Approach Heart Disease Prevention
For decades, cholesterol management has been a cornerstone of cardiovascular care. But new national guidelines from the American Heart Association and the American College of Cardiology (AHA/ACC) are reshaping how clinicians assess risk, when they start treatment, and how aggressively they aim to lower cholesterol. These evidence-based recommendations offer a comprehensive strategy to effectively lower an individual’s risk of developing atherosclerotic cardiovascular disease (ASCVD).
Considering More Factors
One of the most important changes in the new recommendations is how clinicians estimate cardiovascular risk. Traditional tools relied heavily on a limited set of factors like age, cholesterol levels, blood pressure, and smoking status to predict the likelihood of a heart attack or stroke.
The updated approach introduces a more refined risk calculator that incorporates newer data and reflects the reality that cardiovascular event rates have declined over time. As a result, treatment thresholds are now lower, allowing clinicians to intervene earlier.
These new equations, called Predicting Risk of cardiovascular disease EVENTs (American Heart Association PREVENT), are designed to estimate cardiovascular disease risk based on cardiovascular, kidney, and metabolic health factors, but also to encourage doctor-patient discussion. The process considers additional factors such as family history, chronic inflammatory conditions, and emerging biomarkers. This shift recognizes that heart disease develops through multiple pathways—and that two people with similar cholesterol levels may have very different underlying risks.
New Testing Recommendations
Selective use of a non-contrast coronary artery calcium (CAC) scan to identify calcium deposits in the arteries can help determine whether cholesterol is already causing damage.
These new guidelines recommend CAC scans for men aged 40 and older and women aged 45 and older with borderline or intermediate 10-year risk of heart attack to help guide the decision to prescribe a statin or not. This approach allows clinicians to accurately assess plaque buildup in the walls of the heart’s arteries when a person’s true ASCVD risk is unclear.
For patients with no detectable calcium, treatment can often be safely delayed, sparing them from unnecessary medication. For those with even small amounts of plaque, the strategy shifts toward more aggressive prevention.
The guidelines also suggest that Lipoprotein (a), or Lp(a), should be measured at least once in adulthood. High levels are associated with increased long-term risk of heart attack or stroke, so awareness can help guide overall assessment of risk. Because these levels are largely determined by genetics and remain relatively stable over a lifetime, repeat testing isn’t necessary.
For some patient populations, measuring Apolipoprotein B (apoB) may help assess residual ASCVD risk and guide treatment. ApoB may be a more accurate risk marker than Lp(a) for people with conditions such as cardiovascular-kidney-metabolic syndrome, Type 2 diabetes, high triglycerides, or known cardiovascular disease.
Revised Cholesterol Targets
Another major shift is the return of clear LDL-C and high-density lipoprotein cholesterol (non-HDL-C) goals. Earlier guidelines moved away from setting strict targets, but mounting evidence has led to a reversal. The new guidelines provide targets based on risk: the higher the risk, the lower the target.
Patients with established cardiovascular disease or multiple risk factors are now encouraged to achieve very low LDL cholesterol levels—the type most closely linked to plaque buildup. In many cases, this means aiming for levels well below what was once considered sufficient.
For those at borderline or intermediate risk, the LDL-C goal should be less than 100 mg/dL; for those at high risk, less than 70 mg/dL. For individuals at very high risk of ASCVD events, the LDL-C goal is less than 55 mg/dL.
This change reflects a growing body of research showing that lowering LDL cholesterol not only slows disease progression but can stabilize existing plaque, making it less likely to rupture and cause a heart attack.
Expanding the Treatment Toolbox
While statins remain the foundation of cholesterol management, a range of newer therapies now allows clinicians to tailor treatment more precisely and help more patients reach their targets. This flexibility is especially important for patients who cannot tolerate high-dose statins or who need more intensive treatment than statins alone can provide.
These include medications that reduce cholesterol absorption, as well as injectable therapies that dramatically lower LDL levels. These include ezetimibe and/or bempedoic acid, an injectable PCSK9 monoclonal antibody, and Inclisiran, another injectable currently in clinical trials.
For patients with hypertriglyceridemia (elevated triglycerides), additional treatments have been shown to reduce cardiovascular risk when added to standard therapy. While lifestyle changes and statin therapy are still the core strategies to manage hypertriglyceridemia, other therapies may be needed based on a patient’s ASCVD and pancreatitis risk.
A Shift Toward a Long-Term Approach
The updated guidance stresses the importance of early action. Heart disease develops over decades, and the cumulative exposure to elevated cholesterol plays a central role.
This shifts the emphasis to identifying high-risk individuals earlier in life, particularly those with inherited conditions that cause very high cholesterol levels from a young age. For these patients, early treatment can dramatically reduce lifetime risk.
Cholesterol screening is recommended for all children between the ages of 9 and 11, and again between 17 and 21, and for higher-risk children, even earlier (between ages 2 and 8).
At the same time, clinicians are balancing this approach with caution, recognizing that not every patient with mildly elevated cholesterol requires medication. Lifestyle changes remain the foundation of prevention, especially for those at lower risk.
Related: